Skip to main content

Table 1 Demographic, clinical, laboratory and treatment characteristics of children included in the MISCO Study

From: Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study)

Demographic characteristics n = 78
Age in years, median (IQR) 7 (1 - 11)
Male sex, n (%) 46 (59)
Origin according to altitude, n(%)  
 > 1,500 MASL 69 (88.5)
 < 1,500 MASL 9 (11.5)
Nutritional status, n (%)  
 Obesity 23 (29.5)
 Overweight 6 (7.7)
 Normal 45 (57.7)
 Undernutrition 4 (5.1)
Days in PICU, median (IQR) 6 (4 – 7)
Death, n (%) 7 (9)
Days from onset of symptoms to admission to PICU (IQR)  
 Survivors 5 (1-92)
 No survivors 6 (3-12)
Clinical characteristics  
Days from onset of symptoms and test, median (IQR) 4 (3 – 5)
Days of fever, median (IQR) 5 (3.75 – 6)
Organ involvement  
Skin and mucous membranes, n (%)  
 Lips/tongue 17 (22)
 Hand/foot edema 34 (44)
 Conjunctival injection 23 (29.5)
Gastrointestinal, n(%)  
 Diarrhea 55 (70.5)
 Vomiting 58 (74)
 Abdominal pain 55 (70.5)
Neurological disorders, n (%)  
 Headache 17 (22)
Cardiovascular  
 Shock 68 (87)
 Hypotension 61 (78)
 Cardiac dysfunction ₸ 14 (19)
 Coronary artery dilation or aneurysms₸ 27 (35)
 Mitral regurgitation₸ 16 (21)
 Aortic regurgitation₸ 2 (2.5)
 Pericardial effusion₸ 27 (36)
 Arrhythmias 5 (6)
 Elevated troponin 38/75 (51)
 Elevated proBNP (> 400 pg/m) 27/33 (82)
Renal, n (%)  
 Acute kidney injury 23 (29)
Respiratory  
 Lower PaO2/FiO2, median (IQR)** 152 (98 - 260)
 Higher oxygenation index, median (IQR) *** 14 (8.7 – 25.5)
Hematological, n(%)  
 Elevated D-dimer > 3,000 ng/ml 41 (55)
 Anemia 36 (46)
 Thrombocytopenia 28 (36)
 Lymphopenia* 50 (64)
 Elevated PTT 15 (19)
 Elevated PT 8 (10)
Other, n(%)  
 Cervical lymphadenopathy > 1.5 cm 18 (23)
SARS COV-2 Labs, n (%)  
Positive PCR 52 (67)
Positive antigen 1 (1)
Negative PCR/Positive serology 15 (19)
Positive serology 10 (13)
Treatment  
Immunoglobulin 71 (91%)
Immunomodulator (eculizumab) 1 (1%)
Steroids 55 (70.5%)
Antivirals (Lopinavir) 1 (1%)
Antiplatelet drugs 34 (44%)
Anticoagulants 34 (44%)
Vasoactive drugs, n (%) 59 (76%)
 Days of vasoactive drug use, median (IQR) 3 (2-5)
 Vasoactive -Inotropic score(VIS), median (IQR) 21 (10 – 35)
Respiratory support¶  
 HFNC 24 (31%)
 NIV 3 (4%)
 Conventional MV 22 (28%)
 HFOV 5 (6.4%)
Dialysis (RRT) 9 (11.5%)
  1. ₸ In 75 patients who had an echocardiogram. * Lymphopenia less than 4500 cells /uL. ** Lower Pa02/Fi02 during PICU stay. ***Higher oxygenation index (OI) during PICU stay. PT – prothrombin time. PTT – partial thromboplastin time. HFNC – high-flow nasal cannula. NIV – noninvasive ventilation. MV – mechanical ventilation. HFOV – high-frequency oscillatory ventilation. RRT – renal replacement therapy. MASL --meters above sea level. ¶ A single patient may have had more than one of the described respiratory supports during his/her PICU stay